MCM
ENTA icon

MAI Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

MAI Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.24K Buy
177
+170
+2,429% +$2.28K ﹤0.01% 3878
2025
Q4 		$111 Buy
+7
New +$89 ﹤0.01% 4149

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MAI Capital Management's ENTA Position: Q1 2026 in Review

MAI Capital Management increased its Enanta Pharmaceuticals (ENTA) stake by 2,429% in Q1 2026, buying an estimated $2.28K and bringing the position to 177 shares worth $2.24K. The position accounts for ﹤0.01% of the portfolio, ranked #3878.

MAI Capital Management first reported a position in ENTA in Q4 2025 and has held it in 2 quarters since. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • MAI Capital Management held 177 shares of Enanta Pharmaceuticals worth $2.24K as of Q1 2026.
  • MAI Capital Management bought 170 Enanta Pharmaceuticals shares in Q1 2026, an estimated $2.28K.
  • Enanta Pharmaceuticals made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #3878 holding.
  • MAI Capital Management first reported a position in Enanta Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.